LONDON, UK / ACCESSWIRE / December 26, 2017 / Active-Investors has a free review on Xcel Energy Inc. (NYSE: XEL) following the Company’s announcement that it will begin trading ex-dividend on December 27, 2017. To capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date that is by latest at the end of the trading session on December 26, 2017. Active-Investors has initiated due-diligence on this dividend stock. Register with us for more free research including the one on XEL:

www.active-investors.com/registration-sg/?symbol=XEL

If your portfolio includes dividend stocks, you have come to the right place for timely information. All you need to do is sign up for your free membership at:

www.active-investors.com/registration-sg

Dividend Declared

On December 13, 2017, Xcel Energy’s Board of Directors declared a quarterly dividend on its common stock of $0.36 per share. The dividends are payable January 20, 2018, to shareholders of record on December 28, 2017.

Xcel Energy’s indicated dividend represents a yield of 2.97%, which is substantially above the average dividend yield of 2.38% for the Utilities sector. The Company has raised dividend for thirteen consecutive years.

Dividend Insights

Xcel Energy has a dividend payout ratio of 62.3%, this represents that the Company spends approximately $0.62 for dividend distribution out of every $1.00 earned. The dividend payout ratio reflects how much amount a company is returning to shareholders versus how much money it is keeping on hand to reinvest in growth, to pay off debt, and/or to add to its cash reserves.

According to analysts’ estimates, Xcel Energy is forecasted to report earnings of $2.45 per share for the next year, which is substantially above the Company’s annualized dividend of $1.44 per share.

As of October 24, 2017, Xcel Energy’s Liquidity totaled $2.31 billion. For the nine months ended September 30, 2017, the Company’s net cash provided by operating activities totaled $2.37 billion compared to $2.43 billion for the year-ago same period. The Company’s strong financial position indicates its ability to absorb any fluctuations in earnings and cash flow and to sustain the dividend distribution for a long period.

Recent Development for Xcel Energy

On December 19, 2017, Xcel Energy announced that it will voluntarily transfer its stock exchange listing from the New York Stock Exchange (NYSE) to the Nasdaq Global Select Market (NASDAQ), effective December 29, 2017, after the market close. Xcel Energy’s shares are expected to begin trading as a Nasdaq-listed security on January 02, 2018. The Company will retain its current ticker symbol “XEL”.

About Xcel Energy Inc.

Xcel Energy is a major US electricity and natural gas Company with operations in 8 Western and Midwestern states. Xcel Energy provides a comprehensive portfolio of energy-related products and services to 3.6 million electricity customers and 2.0 million natural gas customers through its regulated operating companies. Company headquarters are located in Minneapolis.

Stock Performance Snapshot

December 22, 2017 – At Friday’s closing bell, Xcel Energy’s stock marginally fell 0.29%, ending the trading session at $48.25.

Volume traded for the day: 3.10 million shares, which was above the 3-month average volume of 3.03 million shares.

Stock performance in the last three-month – up 1.15%; previous six-month period – up 1.84%; past twelve-month period – up 18.64%; and year-to-date – up 18.55%

After last Friday’s close, Xcel Energy’s market cap was at $24.57 billion.

Price to Earnings (P/E) ratio was at 20.72.

The stock has a dividend yield of 2.98%.

The stock is part of the Utilities sector, categorized under the Electric Utilities industry. This sector was up 0.2% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484916

LONDON, UK / ACCESSWIRE / December 26, 2017 / Active-Investors.com has just released a free earnings report on Air Lease Corp. (NYSE: AL). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AL. The Company posted its financial results on November 09, 2017, for the third quarter fiscal 2017 (Q3 FY17). The Los Angeles, California-based Company’s total revenues and diluted EPS grew 6.1% and 4.7% y-o-y, respectively; outperforming market consensus estimates. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Air Lease most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=AL

Earnings Highlights and Summary

During Q3 FY17, Air Lease posted total revenues of $376.77 million, up from $355.10 million recorded at the end of Q3 FY16. Total revenues numbers for the reported quarter topped market expectations of $374.61 million. Rental of flight equipment revenues were $359.49 million compared to $340.86 million in the last year’s comparable quarter. Furthermore, aircraft sales, trading and other revenues amounted to $17.28 million in the reported quarter, rising from $14.24 million in Q3 FY16.

The Company that leases planes to airlines reported net income of $99.19 million, or $0.90 per diluted share in Q3 FY17, up from $93.28 million, or $0.86 per diluted share, in Q3 FY16. Meanwhile, Wall Street had expected to report adjusted diluted EPS of $0.80

Operating Metrics

In the three months ended on September 30, 2017, the Company incurred selling, general, and administrative (SG&A) expenses of $19.26 million compared to $19.87 million in the prior year’s same quarter. The Company’s total expenses for the reported quarter stood at $222.65 million compared to $210.53 million in the prior year’s corresponding quarter. Furthermore, the Company reported adjusted net income before income taxes of $166.44 million, or $1.50 per diluted share, in Q3 FY17 versus $157.26 million, or $1.43 per diluted share, in Q3 FY16.

Air Lease posted pre-tax margin of 40.9% for Q3 FY17 compared to 40.7% in Q3 FY16. The Company’s trailing twelve months ended September 30, 2017, adjusted pre-tax return on equity was 18.5% versus 19.0% in the last year’s comparable quarter.

As of September 30, 2017, the Company’s fleet comprised of 236 owned aircraft, with a weighted-average age and remaining lease term of 3.7 years and 6.8 years, respectively, and 51 managed aircraft. Furthermore, Air Lease took delivery of three new aircraft and sold seven aircraft from its operating lease portfolio during Q3 FY17.

Balance Sheet

The Company’s net cash provided by operating activities was $751.64 million in the first nine months of FY17, compared to $761.48 million in the prior year’s comparable period. The Company had cash and cash equivalents balance of $226.02 million, as on September 30, 2017, compared to $274.80 million, at the close of books on December 31, 2016.

Dividend and Share Repurchase

In its earnings press release, Air Lease’s Board of Directors hiked the quarterly cash dividend by 33% from $0.075 per share to $0.10 per share. The dividend is payable on January 04, 2018, to holders of common stock on record as of December 14, 2017.

Stock Performance Snapshot

December 22, 2017 – At Friday’s closing bell, Air Lease’s stock slightly climbed 0.78%, ending the trading session at $47.82.

Volume traded for the day: 589.88 thousand shares.

Stock performance in the last month – up 14.90%; previous three-month period – up 16.86%; past twelve-month period – up 35.93%; and year-to-date – up 39.30%

After last Friday’s close, Air Lease’s market cap was at $4.90 billion.

Price to Earnings (P/E) ratio was at 13.74.

The stock has a dividend yield of 0.84%.

The stock is part of the Services sector, categorized under the Rental & Leasing Services industry. This sector was flat at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484917

LONDON, UK / ACCESSWIRE / December 26, 2017 / Active-Investors.com has just released a free research report on BioLine Rx Ltd (NASDAQ: BLRX) (“BioLineRx”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BLRX as the Company’s latest news hit the wire. On December 21, 2017, the Company, a clinical-stage biopharmaceutical Company focused on oncology and immunology, announced that it has initiated its Phase-3 GENESIS clinical trial, wherein its stem cell mobilization asset, BL-8040, will be compared to placebo, on top of granulocyte colony-stimulating factor (G-CSF), for the mobilization of hematopoietic stem cells (HSCs) used for autologous transplantation in multiple myeloma patients. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, BioLine Rx most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=BLRX

About BL-8040

BL-8040 is the main therapeutic candidate of BioLineRx. It is a short peptide for the treatment of stem cell mobilization, acute myeloid leukemia, and solid tumors. It has shown strong stem-cell mobilization, including the mobilization of colony-forming cells T, B, and NK cells. BL-8040 functions as a high-affinity antagonist for CXCR4, with long receptor occupancy. Mostly, CXCR4 gets over-expressed in over 70% of human cancers and its expression intensifies the disease severity.
BioLineRx has successfully completed the Phase-2a study of BL-8040 for treating relapsed/refractory Acute Myeloid Leukemia (AML). The Company is also in the middle of a Phase-2b study as an AML consolidation treatment, and has initiated a Phase-3 study in stem cell mobilization for autologous transplantation.
In its clinical and pre-clinical studies, BL-8040 has demonstrated vigorous mobilization of cancer cells and immune-cells from the bone marrow, which in turn, sensitives cancer cells to chemo- and bio-based anti-cancer therapy, and directs anti-cancer effect by inducing cell death (apoptosis) and mobilizing immune-cells.
BioLineRx from Biokine Therapeutics had licensed BL-8040, which was previously sold under the name BKT-140.

Phase-3 Study Design

The Phase-3 study, which has been named the GENESIS study, is a randomized, placebo-controlled, multicenter study, that aims to evaluate the safety, tolerability, and efficacy of BL-8040 and G-CSF compared to placebo and G-CSF, for the mobilization of HSCs for autologous transplantation in multiple myeloma patients.
The study will start with a lead-in period for dose confirmation with about 10 to 30 patients. Post that, it will proceed to the placebo-controlled main part, which will cover a total of 177 patients in over 15 centers.
The treatment will include about 5-8 days of G-CSF, with a single dose of BL-8040 or placebo on day 4. The apheresis for stem cell collection will be performed on the fifth day while more apheresis sessions would be conducted if needed in order to reach the benchmark of ≥ 6×106 mobilized HSCs.

Primary and Secondary Objectives

The primary objective of the study is to validate that BL-8040, on top of G-CSF, is greater than G-CSF alone in the ability of mobilizing ≥ 6×106 HSCs in up to 2 aphereses. The secondary objective comprise time to engraftment of neutrophils and platelets, and durability of engraftment, as well as other efficacy and safety parameters.

An Important Development in the Field of Oncology

The commencement of the Phase-3 trial for BL-8040 is a significant milestone in the development of BioLineRx’s lead oncology platform. Treatment with BL-8040 as a single administration and up-to-two-day collection regimen for rapid mobilization of stem cells would lead to a significant improvement from the existing treatment, which requires up to four apheresis sessions. The top-line results from the Phase-3 study are expected in 2020.

Dr. John F. DiPersio, Chief, Division of Oncology at the Washington University School of Medicine, is serving as the lead investigator for the study. He is thrilled to evaluate the role of BL-8040, which is a novel CXCR4 inhibitor with G-CSF for the mobilization of peripheral blood stem cells from patients undergoing autologous transplant for multiple myeloma. He expects that this would give way to another approach for the optimal hematopoietic stem cell collection in this challenging group of patients.

Stock Performance Snapshot

December 22, 2017 – At Friday’s closing bell, BioLine Rx’s stock rose 1.79%, ending the trading session at $1.14.

Volume traded for the day: 417.41 thousand shares.

Stock performance in the last month – up 10.68%; previous six-month period – up 32.56%; past twelve-month period – up 16.33%; and year-to-date – up 23.91%

After last Friday’s close, BioLine Rx’s market cap was at $118.69 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484918

LONDON, UK / ACCESSWIRE / December 26, 2017 / Active-Investors.com has just released a free earnings report on C&J Energy Services, Inc. (NYSE: CJ) (“C&J Energy”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CJ. The Company posted its financial results on November 09, 2017, for the third quarter of the fiscal year 2017. The Houston, Texas-based Company reported a 90.4% surge in quarterly revenues. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, C&J Energy Services most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=CJ

Earnings Highlights and Summary

In Q3 FY17, C&J Energy posted revenues of $442.65 million, which came in above the $232.54 million recorded at the end of Q3 FY16. However, the Company’s total revenue numbers fell short of market expectations of $445.87 million. The Company attributed the growth during the reported quarter to strong activity levels, higher utilization, and pricing in its Completion Services segment.

The oil & gas equipment and services Company reported a net income of $10.48 million, or $0.17 per diluted share, in Q3 FY17 versus a net loss of $106.39 million, or $0.90 per diluted share, in Q3 FY16. Meanwhile, market analysts had forecasted a net income of $0.07 per diluted share for Q3 FY17.

Earnings Metrics

For Q3 FY17, the Company’s direct costs were $339.98 million, up from the $216.84 million spent in the last year’s same quarter. The Company’s selling, general, and administrative expenses (SG&A) were $59.64 million for the reported quarter versus $48.83 million in Q3 FY16, while Research and Development (R&D) expenses were down to $1.67 million in Q3 FY17 from $1.80 million in Q3 FY16. The Company’s operating income for the reported quarter stood at $6.41 million compared to an operating loss of $85.55 million in Q3 FY16. Furthermore, C&J Energy’s adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) was $43.90 million for the reported quarter versus a negative adjusted EBIDTA of $17.91 million in the prior year’s comparable quarter.

Segment Performance

During Q3 FY17, the Completion Services segment’s revenues increased to $344.94 million from $140.20 million in Q3 FY16. The segment posted an operating income of $45.76 million in Q3 FY17 compared to an operating loss of $42.69 million in the prior year’s corresponding quarter. Furthermore, the segment’s adjusted EBITDA was $69.02 million for Q3 FY17 versus a negative adjusted EBITDA of $6.09 million in Q3 FY16.

The Well Support Services segment reported revenues of $97.71 million in Q3 FY17 compared to $90.31 million in Q3 FY16. The segment’s operating loss came in at $10.026 million for Q3 FY17 compared to an operating loss of $11.65 million in the previous year’s same quarter. Additionally, the segment posted an adjusted EBITDA of $0.79 million in Q3 FY17 compared to $6.82 million in Q3 FY16.

Cash Matters

During the nine months ended September 30, 2017, C&J Energy used $60.83 million of cash for its operating activities versus $82.74 million in the prior year’s same period. The Company’s cash and cash equivalents balance stood at $213.12 million as on September 30, 2017, compared to $64.58 million at the close of books as on December 31, 2016.

Stock Performance Snapshot

December 22, 2017 – At Friday’s closing bell, C&J Energy Services’ stock marginally fell 0.29%, ending the trading session at $33.89.

Volume traded for the day: 242.91 thousand shares.

Stock performance in the last month – up 13.61%; previous three-month period – up 11.52%; and past six-month period – up 7.42%

After last Friday’s close, C&J Energy Services’ market cap was at $2.15 billion.

Price to Earnings (P/E) ratio was at 9.02.

The stock is part of the Basic Materials sector, categorized under the Oil & Gas Equipment & Services industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484919

LONDON, UK / ACCESSWIRE / December 26, 2017 / Active-Investors.com has just released a free earnings report on The Walt Disney Co. (NYSE: DIS). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=DIS. The Company posted its financial results on November 09, 2017, for the fourth quarter fiscal 2017. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, The Walt Disney most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=DIS

Earnings Highlights and Summary

For three months ended September 30, 2017, Walt Disney’s revenues decreased 3% to $12.78 billion from $13.14 billion in Q4 FY16. The Company’s revenue was below analysts’ expectations of $13.23 billion.

During FY17, the Company’s revenue decreased 1% to $55.14 billion from $55.63 billion in FY16.

For the reported quarter, the Company’s segment operating income decreased 11% to $2.81 billion from $3.18 billion in Q4 FY16.

During Q4 FY17, Walt Disney’s earnings before tax (EBT) decreased 6.5% to $2.69 billion from $2.88 million in the same period last year. For the reported quarter, the Company’s EBT margin decreased 80 basis points to 21.1% of revenue from 21.9% of revenue in Q4 FY16.

For the reported quarter, Walt Disney’s net income decreased 1.4% to $1.87 billion from $1.89 billion in Q4 FY16. During Q4 FY17, the Company’s diluted EPS increased 3% to $1.13 on a y-o-y basis from $1.10 in the same period last year. For the reported quarter, Walt Disney’s adjusted net income decreased 6.9% to $1.77 billion from $1.90 billion in Q4 FY16. During Q4 FY17, the Company’s adjusted diluted EPS decreased 3% to $1.07 from $1.10 in the same period last year. Adjusted diluted EPS was below analysts’ expectations of $1.13.

During FY17, the Company’s net income decreased 4% to $8.98 billion from $9.39 billion in FY16. During FY17, the Company’s diluted EPS decreased 1% to $5.69 from $5.73 in FY16. During FY17, the Company’s adjusted diluted EPS was $5.70 compared to $5.72 in FY16.

Segment Details

Media Networks – During Q4 FY17, the Media Networks segment’s revenues decreased 3% to $5.47 billion from $5.66 billion in the same period last year. For the reported quarter, the segment’s operating income decreased 12% to $1.48 billion from $1.67 billion in Q4 FY16.

Parks and Resorts – During Q4 FY17, the Parks and Resorts segment’s net revenue increased 6% to $4.67 billion from $4.39 billion in the same period last year. For the reported quarter, the segment’s operating income increased 7% to $746 million from $699 million in Q4 FY16.

Studio Entertainment – During Q4 FY17, the Studio Entertainment segment’s net revenue decreased 21% to $1.43 billion from $1.81 billion in the same period last year. For the reported quarter, the segment’s operating income decreased 43% to $218 million from $381 million in Q4 FY16.

Consumer Products & Interactive Media – During Q4 FY17, the Consumer Products & Interactive Media segment’s net revenue decreased 6% to $1.22 billion from $1.29 billion in the same period last year. For the reported quarter the segment’s operating income decreased 12% to $373 million from $424 million in Q4 FY16.

Balance Sheet

As on September 30, 2017, Walt Disney’s cash and cash equivalents decreased 12.9% to $4.02 billion from $4.61 billion on October 01, 2016.

For the reported quarter, the Company’s receivables decreased 4.8% to $8.63 billion from $9.07 billion in Q4 FY16. For the reported quarter, the Company’s accounts payable and other accrued liabilities decreased 3% to $8.86 billion from $9.13 billion in Q4 FY16.

During FY17, Walt Disney’s net cash provided by operating activities decreased 6% to $12.34 billion from $13.14 billion in FY16. During FY17, Walt Disney’s free cash flow increased 4% to $8.72 billion from $8.36 billion in FY16.

On November 29, 2017, the Company’s Board of Directors announced a semi-annual cash dividend of $0.84 per share, payable on January 11, 2018, to shareholders of record at the close of business on December 11, 2017.

Stock Performance Snapshot

December 22, 2017 – At Friday’s closing bell, The Walt Disney’s stock was marginally down 0.82%, ending the trading session at $108.67.

Volume traded for the day: 7.37 million shares.

Stock performance in the last month – up 5.77%; previous three-month period – up 9.14%; past twelve-month period – up 3.08%; and year-to-date – up 4.27%

After last Friday’s close, The Walt Disney’s market cap was at $165.48 billion.

Price to Earnings (P/E) ratio was at 19.13.

The stock has a dividend yield of 1.55%.

The stock is part of the Services sector, categorized under the Entertainment – Diversified industry. This sector was flat at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484911

LONDON, UK / ACCESSWIRE / December 26, 2017 / Active-Investors.com has just released a free research report on vTv Therapeutics Inc. (NASDAQ: VTVT). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VTVT as the Company’s latest news hit the wire. On December 21, 2017, the clinical-stage biopharmaceutical Company that works towards the development of orally-administered, small molecule drug candidates to fulfill unmet medical needs, declared that it has entered into a licensing agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd (“Huadong Pharmaceutical”), a wholly-owned subsidiary of Huadong Medicine Co., Ltd for the rights to develop and commercialize vTv Therapeutics’ GLP-1r agonist program (TTP273) in China and other Pacific Rim countries for the treatment of Type 2 Diabetes. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, vTv Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=VTVT

About TTP273

TTP273 is an oral small molecule GLP-1r agonist. It activates GLP-1 receptors, which leads to the enhancement of insulin secretion and suppression of glucagon production and decreased food intake. At present, there are several injectable GLP-1 peptide therapies in the market, which have exhibited a significant reduction in glucose levels in addition to weight loss. However, their use is restricted due to the route of administration (i.e. injection), and by the high incidence of gastrointestinal side effects such as nausea and vomiting.

In its Phase-2 Trial, TTP273 met its primary endpoint and showed a statistically significant reduction in HbA1c for Type 2 Diabetes. The compound was well tolerated, with negligible incidences of nausea and vomiting across all fields of the study.

Increasing Incidence of Type 2 Diabetes

Type 2 Diabetes results from the body’s inability to use insulin properly to control sugar in the bloodstream. Of the total diabetes patients globally, around 95% represent Type 2 diabetes.

Diabetes is the 7th major cause of death in the United States, which costs the healthcare system approximately $245 billion every year. As per the American Diabetes Association, there are over 29.1 million Americans, or 9.3% of the population, living with diabetes. In fact, the number of people with Type 2 Diabetes has quadrupled over the last 35 years, and currently there are about 160 million people with diabetes in the Western Pacific region.

Terms of the Agreement

Under the agreement, vTv Therapeutics has granted Huadong Pharmaceutical an exclusive license to develop, manufacture, and commercialize its GLP-1r agonist program in China, Hong Kong, Macau, Taiwan, Thailand, Vietnam, Indonesia, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos, Brunei, South Korea, and Australia.

Besides, the agreement also authorizes vTv Therapeutics to run a Phase-2 Multi-Regional Clinical Trial (MRCT) including sites in the US and other regions in the Pacific Rim.

Total Compensation for the Transaction

The agreement entitles vTv Therapeutics to receive an upfront payment of $8 million, subject to satisfaction of certain customary conditions. Apart from that, the Company is eligible for milestone payments up to $75 million, related to development, regulatory, and commercial milestones. Moreover, vTv Therapeutics would also get royalty payments on sales of commercialized products in the territories.

Agreement Aims to Expand Options for Treatment of Type 2 Diabetes

This agreement between vTv Therapeutics and Huadong Pharmaceutical has the potential to expand treatment options for patients with Type 2 diabetes in Asian countries, where there is a medical need for an oral small molecule therapy that has the same benefits as the injectable diabetes GLP-1 peptides, without the commonly associated side effects.

Huadong Pharmaceutical is a comprehensive pharmaceutical Company that integrates traditional Chinese medicine, western medicine, biotech products API, and dosage forms. The Company is one of the leading domestic manufacturers in China and has developed a series of drugs in the field of diabetes treatment. Diabetes medications comprise its core product line and key area of its research and development (R&D) and innovative drug strategy. The agreement with vTv Therapeutics would accelerate its transformation from a generic drug Company to an innovative drug Company, and advance its mission of providing more and better products to a greater number of patients.

Stock Performance Snapshot

December 22, 2017 – At Friday’s closing bell, vTv Therapeutics’ stock declined 6.32%, ending the trading session at $4.15.

Volume traded for the day: 118.04 thousand shares, which was above the 3-month average volume of 50.24 thousand shares.

After last Friday’s close, vTv Therapeutics’ market cap was at $145.42 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484912

LONDON, UK / ACCESSWIRE / December 26, 2017 / Active-Investors.com has just released a free earnings report on Wheaton Precious Metals Corp. (NYSE: WPM). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=WPM. The Company posted its financial results on November 09, 2017, for the third quarter of the fiscal year 2017.Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Wheaton Precious Metals most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=WPM

Earnings Highlights and Summary

For the three months ended September 30, 2017, Wheaton Precious Metals’ revenues decreased 12.9% to $203.03 million from $233.20 million in Q3 FY16. The Company’s revenue numbers were below analysts’ expectations of $220.82 million.

During Q3 FY17, Wheaton Precious Metals’ gross profit decreased 15.8% to $82.95 million from $98.51 million in the same period of last year. For the reported quarter, the Company’s gross margin decreased 130 basis points to 40.9% of revenue from 42.2% of revenue in Q3 FY16.

During Q3 FY17, Wheaton Precious Metals’ earnings before tax (EBT) decreased 18.7% to $66.32 million from $81.61 million in the comparable period of last year. For the reported quarter, the Company’s EBT margin decreased 230 basis points to 32.7% of revenue from 35% of revenue in Q3 FY16.

For the reported quarter, Wheaton Precious Metals’ net income decreased 20% to $66.58 million from $82.99 million in Q3 FY16. During Q3 FY17, the Company’s diluted earnings per share (EPS) decreased 21.1% to $0.15 from $0.19 in the corresponding period of last year, and was below analysts’ expectations of $0.16.

Segment Details

Silver – During Q3 FY17, the Company’s Silver segment’s revenue decreased 18.8% to $97.13 million from $119.57 million in the same period of last year. For the reported quarter, the segment’s average realized price decreased 13.6% to $16.87 from $19.53 in Q3 FY16. For the reported quarter, the Company’s total silver ounces production decreased 0.7% to 7,595 from 7,651 in Q3 FY16, due to a lower production from the San Dimas mine, resulting from various operational issues. For the reported quarter, the Company’s total silver ounces sales were 5,758 compared to 6,122 in Q3 FY16.

Gold – During Q3 FY17, the Company’s Gold segment’s revenue decreased 6.8% to $105.91 million from $113.63 million in the comparable period of last year. For the reported quarter, the segment’s average realized price decreased 4% to $1,283 from $1,336 in Q3 FY16. For the reported quarter, the Company’s total gold ounces production decreased 15.1% to 95,897 from 113,008 in Q3 FY16, primarily due to a reduction of the Company’s share of the gold production at the 777 mine from 100% to 50%, which became effective on January 01, 2017, coupled with reduced production at Minto. For the reported quarter, the Company’s total gold ounces sales were 82,548 compared to 85,063 in Q3 FY16.

Balance Sheet

As on September 30, 2017, Wheaton Precious Metals’ cash and cash equivalents decreased 43.8% to $69.91 million from $124.30 million as on December 31, 2016.

For the reported quarter, the Company’s accounts receivable increased 154.3% to $5.90 million from $2.32 million in Q4 FY16. For the reported quarter, the Company’s accounts payable and accrued liabilities decreased 28.2% to $13.52 million from $18.83 million in Q4 FY16.

During Q3 FY17, the Company’s cash provided by operating activities decreased 20.1% to $129.12 million from $161.58 million in the corresponding period of last year.

Stock Performance Snapshot

December 22, 2017 – At Friday’s closing bell, Wheaton Precious Metals’ stock was slightly up 0.09%, ending the trading session at $22.03.

Volume traded for the day: 1.15 million shares.

Stock performance in the last month – up 3.23%; previous three-month period – up 14.38%; past twelve-month period – up 27.05%; and year-to-date – up 14.03%

After last Friday’s close, Wheaton Precious Metals’ market cap was at $9.74 billion.

Price to Earnings (P/E) ratio was at 47.27.

The stock has a dividend yield of 1.63%.

The stock is part of the Basic Materials sector, categorized under the Silver industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 484914